Parnax Lab Ltd
₹142.95
(5.95%)
Sun, 31 May 2026, 11:14 pm
Health Technology
Pharmaceuticals: Major
24.5KParnax Lab Share Price Live Chart
1 Day
(5.95%)
No Result Found
Summary
Market Cap
164.19
Net Profit
11.54
P/B
1.48
Sector P/E
33.76
P/E
10.67
EV/EBITDA
6.67
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.81
ROCE (Industry)
16.40
RONW (Industry)
14.39
ROE
14.92
ROCE
13.77
Debt/Equity
0.97
EPS (TTM)
11.72
Dividend Yield
0
Book Value
78.35
Interest Cover
3.91
Analysis
all
- Parnax Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
- Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (21.9%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1x debt.
- Unable to evaluate Parnax Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Parnax Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.
- Parnax Lab is making a loss, therefore interest payments are not well covered by earnings.
- Parnax Lab's level of debt (109.9%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 72.30 | 72.30 | 72.30 | 72.30 | 72.30 |
| FII | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 |
| Public | 27.70 | 27.70 | 27.70 | 27.70 | 27.70 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 237 | 194 | 176 | 151 | 133 | 108 | 65 |
| Fibonacci | 194 | 177.57 | 167.43 | 151 | 134.57 | 124.43 | 108 |
| Camarilla | 169.82 | 165.88 | 161.94 | 151 | 154.06 | 150.12 | 146.18 |
Pivots Level: Classic
R3
+86
237
R2
+43
194
R1
+25
176
S1
-18
133
S2
-43
108
S3
-86
65
Moving Average
Period
Value
10-EMA
151.00
20-EMA
153.05
30-EMA
152.05
50-EMA
148.01
100-EMA
140.20
200-EMA
132.77
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 28 May 2026 | board-meetings | Accounts | |
| 13 Feb 2026 | board-meetings | Quarterly Results, Half Yearly Results | |
| 14 Nov 2025 | board-meetings | Quarterly Results | |
| 13 Aug 2025 | agm | ||
| 17 Sept 2024 | agm | ||
| 11 Aug 2023 | agm | ||
| 11 Aug 2022 | agm | ||
| 01 Jan 2022 | egm | ||
| 14 Aug 2021 | agm |
Peer Comparison
Parnax Lab Ltd
Divis Laboratories Ltd
Torrent Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddys Laboratories Ltd
Parnax Lab Ltd About
Parnax Lab princi pally engaged in the business activities of manufacturingand export of Pharmaceutical Formulations.
Industry
Pharmaceuticals - Indian - Formulations
Founded
1982
Headquarters
CEO
Employees
Contact
Website
http://www.naxparlab.com
compliance@naxparlab.com
Phone
91-022-6825 2525
Location
Gala 114 Bldg No 8, Jogani Ind Complex Chunabhatti, Mumbai, Maharashtra, 400022
Parnax Lab Ltd Company History
| Year | History |
|---|---|
| 2009 |
|
| 2010 |
|
| 2011 |
|
| 2012 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| NAVRATANMAL BADOLA (HUF) | bulk | Sell | 53695 | 55.27 | 18 May 2018 |
| DHEERAJ KUMAR LOHIA | bulk | Buy | 53737 | 58.81 | 24 Apr 2018 |
| BHAVIN Y MEHTA | bulk | Buy | 47315 | 52.25 | 05 Jun 2017 |
| BHAVIN Y MEHTA | bulk | Sell | 47315 | 53.62 | 05 Jun 2017 |
| SETU SECURITIES PVT LTD | bulk | Sell | 78000 | 74.14 | 19 Apr 2017 |
| SETU SECURITIES PVT LTD | bulk | Buy | 2513 | 74.3 | 19 Apr 2017 |
| SETU SECURITIES PVT LTD | bulk | Buy | 88166 | 70.8 | 18 Apr 2017 |
| NIKHIL VORA | bulk | Buy | 50000 | 64.95 | 17 Apr 2017 |
| SETU SECURITIES PVT LTD | bulk | Buy | 48246 | 63.88 | 13 Apr 2017 |
| PORINJUV VELIYATH | bulk | Buy | 100000 | 55.52 | 30 Mar 2017 |